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Sir, 
 
We are grateful for the opportunity to respond to these comments. Prof Lachmann found our 
paper “... impenetrable (as such meta-analyses often are...)”. Our study is not a meta-analysis 
in which patient records from various studies with a more or less similar design are analysed 
jointly to obtain a single pooled estimate of a treatment effect with greater precision than 
individual randomised trials can offer. It is a single study with a detailed protocol agreed in 
advance by 12 population-based cancer registries, from which anonymised individual cancer 
patient records were submitted for virtually all cancer patients diagnosed in their jurisdiction 
(country or region). We applied standardised quality control procedures to these data sets, 
then estimated relative survival for each cancer in each jurisdiction. For countries with more 
than one participating registry we also provided a pooled estimate, but we did not provide an 
overall estimate of survival for all 6 countries combined. On the contrary, our purpose was to 
evaluate international differences and trends in cancer survival, in order to compare the 
overall effectiveness of the various healthcare systems. Such differences cannot be examined 
in randomised trials, only with observational data.  
 
We agree with Prof Lachmann that early diagnosis and treatment improve the outcome for 
many cancers. Our findings suggest that the international differences in survival arise soon 
after diagnosis. Earlier studies based on large random samples of clinical records suggest that 
in Europe, later stage at diagnosis and differences in treatment could account for much of 
those differences
1-4
. We are now evaluating the impact of stage and treatment on the survival 
trends and differentials that we reported. For lung cancer (ICD-10 C34), we will also examine 
small-cell and other lung cancers separately. Mesothelioma (ICD-10 C45) was not included 
in the study. 
 
The size of a population does not determine the cancer survival estimate, but the variance of 
the estimate depends on the number of cases and the lethality of the tumour. We did not 
estimate survival in samples of patients, but for all cancer patients diagnosed and registered 
in each population. All the registries met the quality criteria for inclusion in Cancer incidence 
in five continents, published by the International Agency for Research on Cancer
5
. Analysis 
of variance is not used in population studies of cancer survival. We analysed relative survival 
with maximum likelihood methods for individual data: these are appropriate regression 
models for the excess hazard of death, which underpins relative survival
6,7
, and they are 
analogous to the Cox proportional hazards model for death rates. We reported 95% 
confidence intervals for all the survival estimates by age, sex, cancer, jurisdiction and 
calendar period (webappendix). However, we were not testing a hypothesis that survival is 
higher or lower in a given country, but reporting the patterns and trends of population-based 
cancer survival, just as is routinely done for incidence and mortality, without significance 
tests
5,8
. 
 
The “proportion of cancer registration to the population” presented in the graphic by Dr 
Jinichi Mori and colleagues seems to be the total number of cases included in the survival 
analyses for a given country over the 13 years 1995-2007 divided by the national population. 
If so, this quantity takes no account of differences in population coverage of the data analysed 
from each country (43-100%), or differences in cancer incidence by age and sex, or 
demographic trends. We do not see how the correlation between this quantity and relative 
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survival can be safely interpreted. Regional variation in survival in Australia and Canada is 
small, and within the limits of random variation
9
. 
 
We share the concern of Prof Pritchard and Dr Hickish that politicians may make selective 
use of evidence. We analysed no data on health service structure, and the survival estimates 
we report provide no evidence for or against any particular style of health service 
organisation. Survival in Denmark is broadly similar to that in the UK, but the Danish health 
service is more akin to that of the other Nordic countries, which have higher survival, than it 
is to the UK health system. Conversely, the UK and Canadian health systems are similar, but 
survival is higher in Canada. 
 
We are not convinced by Prof Pritchard and Dr Hickish’s argument that extrapolated values 
of health expenditure as a proportion of gross domestic product (GDPHE) and changes in the 
UK ranking among 10 major developed countries for all-cancer mortality rates can lead to the 
conclusion that “the NHS, in terms of economic input compared with cancer mortality rates 
output, has achieved more [cancer control than those countries] with proportionately less.” 
Cancer mortality trends cannot be expected to respond quickly or exclusively to trends in 
health expenditure, partly because of the time-lags cited above, and partly because important 
long-term preventive measures are not included in health expenditure. Our article documents 
cancer survival trends, which show progress in the UK (and other countries), particularly for 
breast cancer. We made no statement about whether or how the UK health service should be 
reformed or re-organised. 
 
We see no evidence to agree with Prof Pritchard and Dr Hickish (or with other authors
10,11
) 
that cancer mortality rates are “a better measure for determining the effectiveness of services 
... and international comparisons”.  Mortality trends are invaluable, and we reported them, but 
it is not possible to draw conclusions about the effectiveness of health services from trends in 
mortality alone, because mortality rates obviously depend on both incidence and survival. 
Incidence rates and survival estimates refer to the year when the patients were diagnosed; 
mortality rates refer to the year when the persons died
12
. More than 40% of women who die 
of breast cancer in any given year will have been diagnosed at least 5 years previously. 
Mortality trends thus provide a time-lagged and blurred picture of changes in the 
effectiveness of health services. Where survival has been very low for decades, e.g. for lung 
cancer, mortality trends are largely parallel with incidence trends, as our report showed: the 
substantial fall in lung cancer mortality in men is attributable more to the long-term decline in 
tobacco use than to increasingly effective treatment. Further, mortality rates are subject to 
error in certification of the cause of death: quality control of the cause of death is far more 
limited than that for the anatomy, pathology and behaviour of the cancer in population-based 
incidence data, especially at older ages
13,14
. That is why cancer mortality trends are often 
presented with an upper age limit
10,15
, such as 74 years. An increasing proportion of cancer 
patients are diagnosed at 65 years and over, however, and evidence on outcomes for elderly 
cancer patients is also required. Relative survival provides this evidence. It is not affected by 
errors in the cause of death
16
, and we were able to present survival estimates for elderly 
patients (webappendix). 
 
We and others have argued for joint interpretation of trends in incidence, survival and 
mortality to assess progress in cancer control
17,18
. 
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